The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Abstract Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. Methods The subjects were 102 UC patients who...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-08-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-022-02474-9 |
| _version_ | 1828358047375818752 |
|---|---|
| author | Ohtaki Yuichiro Uchiyama Kan Kamiya Hirotaka Moriizumi Eri Yamada Moe Aoki Yuma Watanabe Toshimune Kiryu Sachie Suzuki Sizuka Matsumoto Yoshihiro Ito Zensho Ohkusa Toshifumi Koido Shigeo Saruta Masayuki |
| author_facet | Ohtaki Yuichiro Uchiyama Kan Kamiya Hirotaka Moriizumi Eri Yamada Moe Aoki Yuma Watanabe Toshimune Kiryu Sachie Suzuki Sizuka Matsumoto Yoshihiro Ito Zensho Ohkusa Toshifumi Koido Shigeo Saruta Masayuki |
| author_sort | Ohtaki Yuichiro |
| collection | DOAJ |
| description | Abstract Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. Methods The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. Results The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. Conclusions The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX. |
| first_indexed | 2024-04-14T03:23:44Z |
| format | Article |
| id | doaj.art-6ca23db89d6b49e58d4c49e93a3d8761 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-14T03:23:44Z |
| publishDate | 2022-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-6ca23db89d6b49e58d4c49e93a3d87612022-12-22T02:15:14ZengBMCBMC Gastroenterology1471-230X2022-08-012211710.1186/s12876-022-02474-9The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitisOhtaki Yuichiro0Uchiyama Kan1Kamiya Hirotaka2Moriizumi Eri3Yamada Moe4Aoki Yuma5Watanabe Toshimune6Kiryu Sachie7Suzuki Sizuka8Matsumoto Yoshihiro9Ito Zensho10Ohkusa Toshifumi11Koido Shigeo12Saruta Masayuki13Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDepartment of Microbiota Research, Juntendo University Graduate School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa HospitalDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of MedicineAbstract Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. Methods The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. Results The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. Conclusions The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX.https://doi.org/10.1186/s12876-022-02474-9Ulcerative ColitisMMXBristol Stool Form Scale5-ASAAdherenceMulti-matrix system mesalazine |
| spellingShingle | Ohtaki Yuichiro Uchiyama Kan Kamiya Hirotaka Moriizumi Eri Yamada Moe Aoki Yuma Watanabe Toshimune Kiryu Sachie Suzuki Sizuka Matsumoto Yoshihiro Ito Zensho Ohkusa Toshifumi Koido Shigeo Saruta Masayuki The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis BMC Gastroenterology Ulcerative Colitis MMX Bristol Stool Form Scale 5-ASA Adherence Multi-matrix system mesalazine |
| title | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
| title_full | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
| title_fullStr | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
| title_full_unstemmed | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
| title_short | The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis |
| title_sort | insoluble excretion of multi matrix system mesalazine preparations in patients with ulcerative colitis |
| topic | Ulcerative Colitis MMX Bristol Stool Form Scale 5-ASA Adherence Multi-matrix system mesalazine |
| url | https://doi.org/10.1186/s12876-022-02474-9 |
| work_keys_str_mv | AT ohtakiyuichiro theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT uchiyamakan theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kamiyahirotaka theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT moriizumieri theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yamadamoe theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT aokiyuma theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT watanabetoshimune theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kiryusachie theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT suzukisizuka theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT matsumotoyoshihiro theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT itozensho theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT ohkusatoshifumi theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT koidoshigeo theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sarutamasayuki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT ohtakiyuichiro insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT uchiyamakan insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kamiyahirotaka insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT moriizumieri insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT yamadamoe insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT aokiyuma insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT watanabetoshimune insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT kiryusachie insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT suzukisizuka insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT matsumotoyoshihiro insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT itozensho insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT ohkusatoshifumi insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT koidoshigeo insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis AT sarutamasayuki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis |